RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer

Phase 2

Recruiting

• Conditions: Colorectal Cancer
• Interventions: Drug: RC48-ADC plus Bevacizumab

• Registration Number: NCT05785325
• Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Brief Summary

A phase II clinical study of RC48-ADC combined with Bevacizumab as late-line treatment in patients with HER2-expressed metastatic colorectal cancer. A total of 30 patients are planned to be enrolled.

Detailed Description

This is a single-arm, non-randomized, single-center trial. Enroll 30 patients with HER2-expressed metastatic colorectal cancer and failure of standard therapy. Divide into 2 cohorts, including 10 patients with low HER2 expression (IHC 2+/FISH negative) and 20 patients with high HER2 expression (IHC 2+/FISH positive or IHC3+). Administer RC48-ADC intravenously in combination with bevacizumab 5mg/kg once every two weeks. Medication must be discontinued until disease progression, intolerable toxicity, informed consent is withdrawn, or investigator judgment is made. The primary endpoints is objective response rate (ORR), and secondary endpoints are progression-free survival (PFS), overall survival (OS), and adverse effects (AE).

Study Timeline

• Status Verified: 2022-12
• Study First Submitted: 2023-03-13
• Study First Submitted QC: 2023-03-24
• Study First Posted: 2023-03-27
• Study Start: 2023-08-20
• Last Update Submitted: 2023-10-30
• Last Update Posted: 2023-10-31
• Primary Completion: 2023-12-01
• Study Completion: 2024-12-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Age 18 or above, male or female;
2. Advanced inoperable colorectal cancer confirmed by pathology;
3. At least 1 measurable lesion meeting RECIST v1.1 criteria;
4. Patients who had received at least oxaliplatin, irinotecan, and fluorouracil for advanced or metastatic disease progressed or were intolerant were admitted to the study; Patients who had previously received anti-HER2 therapy such as trastuzumab and lapatinib were allowed to be included;
5. ECOG PS: 0-2 points;
6. Patients with HER2 expression: IHC results 2+ or 3+.
7. Predicted survival ≥12 weeks;
8. Women of childbearing age must already be using reliable contraception or have had a pregnancy test (serum or urine) with negative results within 7 days prior to inclusion and be willing to use an appropriate method of contraception during the trial period and 8 weeks after the last test drug administration. For males, consent is required to use an appropriate method of contraception or surgical sterilization during the trial period and 8 weeks after the last administration of the trial drug;
9. The subjects voluntarily joined the study and signed the informed consent. The subjects had good compliance and cooperated with follow-up visits.

Exclusion Criteria

1. Known allergy to MMAE conjugate of recombinant humanized anti-HER2 monoclonal antibody for injection;
2. Clinical symptoms or diseases of the heart that are not well controlled, such as heart failure of grade 2 or above; b. Unstable angina pectoris; c. Myocardial infarction within 1 year; d. Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;
3. There are contraindications for the use of bevacizumab such as severe active bleeding, severe arteriovenous thrombosis events, gastrointestinal obstruction and perforation, and uncontrolled hypertension
4. Major surgical treatment, open biopsy, or significant traumatic injury was received within 28 years prior to treatment
5. In the investigator's judgment, subjects had other factors that might have led to the termination of the study, such as other serious medical conditions (including mental illness) requiring concomitant treatment, serious laboratory abnormalities, and family or social factors that might have affected subjects' safety or the collection of data and samples.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
RC48-ADC plus Bevacizumab	RC48-ADC plus Bevacizumab	Administer RC48-ADC intravenously in combination with bevacizumab 5mg/kg once every two weeks. Medication must be discontinued until disease progression, intolerable toxicity, informed consent is withdrawn, or investigator judgment is made.

Primary Outcome Measures

Name	Time	Method
Objective Response Rate	From Baseline to disease progress, up to 18 months	Objective Response Rate was defined as the proportion of patients with a best objective response of complete response (CR) or partial response (PR) according to RECIST criteria (version 1.1)

Secondary Outcome Measures

Name	Time	Method
Progression free survival	From Baseline to primary completion date, about 2 years	Progression-free survival is defined as the time from enrollment to the first documented disease progression according to RECIST version 1.1, or to death from any cause, whichever occurred first
Overal survival	From Baseline to primary completion date, about 5 years	Time from randomization to death (from any cause)

Trial Locations

Locations (1)

The second affiliated hospital of Zhejiang University; 🇨🇳 Hangzhou, Zhejinag, China